Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

1.

Factors associated with initiation of prolonged analgesic use among patients in the HIV Outpatient Study (HOPS).

Koeppe J, Lichtenstein K, Armon C, Chmiel JS, Buchacz K, Wood K, Brooks JT; HOPS Investigators.

Clin J Pain. 2011 Oct;27(8):699-706. doi: 10.1097/AJP.0b013e3182169012.

PMID:
21540742
[PubMed - indexed for MEDLINE]
2.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
[PubMed - indexed for MEDLINE]
3.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A; Italian Cohort Naive Antiretrovirals Study Group.

Arch Intern Med. 2002 Oct 14;162(18):2125-32.

PMID:
12374521
[PubMed - indexed for MEDLINE]
4.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

PMID:
15319852
[PubMed - indexed for MEDLINE]
Free Article
5.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
[PubMed - indexed for MEDLINE]
6.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
[PubMed - indexed for MEDLINE]
Free Article
7.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team.

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
[PubMed - indexed for MEDLINE]
8.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

PMID:
17305932
[PubMed - indexed for MEDLINE]
9.

Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP.

J Infect Dis. 2009 Apr 1;199(7):991-8. doi: 10.1086/597124.

PMID:
19220139
[PubMed - indexed for MEDLINE]
Free Article
10.

Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.

Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD; HIV Outpatient Study Investigators.

Clin Infect Dis. 2005 Jan 1;40(1):148-57. Epub 2004 Dec 6.

PMID:
15614705
[PubMed - indexed for MEDLINE]
Free Article
11.

Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.

Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR.

J Infect Dis. 2007 Feb 1;195(3):425-31. Epub 2006 Dec 21.

PMID:
17205482
[PubMed - indexed for MEDLINE]
Free Article
12.

When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.

Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, Thompson M, Fleming P, Dworkin MS; Adult and Adolescent Spectrum of HIV Disease Project Investigators.

Clin Infect Dis. 2003 Oct 1;37(7):951-8. Epub 2003 Sep 12.

PMID:
13130408
[PubMed - indexed for MEDLINE]
Free Article
13.

Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.

Yacisin K, Maida I, Ríos MJ, Soriano V, Núñez M.

AIDS Res Hum Retroviruses. 2008 Jul;24(7):935-40. doi: 10.1089/aid.2008.0069.

PMID:
18593347
[PubMed - indexed for MEDLINE]
14.

Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.

Ho C, Lee S, Wong Kh, Cheng L, Lam M.

HIV Med. 2007 Apr;8(3):181-5.

PMID:
17461862
[PubMed - indexed for MEDLINE]
15.

[Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].

Pavie J, Porcher R, Fournier S, André F, Tournoux C, Palmer P, Rabian C, Jean-Michel M.

Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13. French.

PMID:
16025661
[PubMed - indexed for MEDLINE]
16.

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2005 May;6(3):198-205.

PMID:
15876287
[PubMed - indexed for MEDLINE]
17.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

PMID:
18199042
[PubMed - indexed for MEDLINE]
Free Article
18.

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.

Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandström E.

AIDS. 1998 Nov 12;12(16):2193-202.

PMID:
9833861
[PubMed - indexed for MEDLINE]
19.

Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption.

Molina-Pinelo S, Vivancos J, De Felipe B, Soriano-Sarabia N, Valladares A, De la Rosa R, Vallejo A, Leal M.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):203-6.

PMID:
16760798
[PubMed - indexed for MEDLINE]
20.

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.

European Collaborative Study.

Clin Infect Dis. 2005 Feb 1;40(3):458-65. Epub 2005 Jan 7.

PMID:
15668871
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk